生物活性化合物和心脏纤维化:当前见解和未来前景
Abdul Majid1,2, Fasilat Oluwakemi Hassan1,2, Md Monirul Hoque1,2
1Department of Physiology, College of Medicine, The University of Tennessee Health Science Center, Translational Research Building, Room 318H, 71 S. Manassas, Memphis, TN 38163, USA.
Journal of cardiovascular development and disease
|July 28, 2023
概括
生物活性化合物在治疗心脏纤维化方面表现有前途,这是心力衰竭的关键因素. 它们的抗炎和抗氧化特性可以减少或预防这种情况.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 心脏纤维化,过度的心脏矩阵沉积,驱动心力衰竭的进展.
- 目前心肌纤维化治疗方法仍然有限.
- 生物活性化合物提供了潜在的抗纤维菌治疗策略.
研究的目的:
- 审查心脏纤维化机制和当前治疗限制.
- 探索生物活性化合物作为抗纤维菌剂.
- 突出预防/减少心脏纤维化的治疗潜力.
主要方法:
- 关于心脏纤维化的综合文献综述.
- 纤维生成的分子机制的分析.
- 评估生物活性化合物的抗纤维素特性.
主要成果:
- 生物活性化合物具有抗炎和抗氧化作用.
- 这些化合物调节细胞外基质的产生和纤维细胞分化.
- 有潜力抑制或促进纤维成分的分解.
结论:
- 生物活性化合物代表了对心脏纤维化的有希望的治疗途径.
- 用这些化合物准纤维化过程可以预防心力衰竭.
- 需要进一步的研究,以便在心脏纤维化治疗中获得临床应用.
相关概念视频
Myocarditis I: Introduction
10
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
10
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Heart Failure Drugs: Inotropic Agents
626
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
626
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Pathophysiology of Cardiac Performance
706
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
706


